Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: drug prices

Executive Order Ties U.S. Drug Prices to Lowest Global Rates

From the College  |  June 23, 2025

In May, the Trump administration published an executive order requiring drug companies to bring prices in line with those paid by other developed nations, otherwise known as Most Favored Nation (MFN) pricing. Although the June 11 deadline has come and gone, no details have been released as to whether drug companies have opted to negotiate or if the government will implement any enforcement action.

Filed under:Legal Updates Tagged with:drug pricingMost Favored Nation

What’s in the New Biden Plan to Reduce U.S. Drug Prices?

Ahmed Aboulenein  |  November 4, 2021

WASHINGTON (Reuters)—U.S. President Joe Biden and his fellow Democrats promised voters sweeping drug price reform in their signature social spending bill but agreed to move ahead with a far less ambitious proposal after facing opposition in Congress. The plan could still fail as hurdles remain to approving the broader spending package, known as “Build Back…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:drug costshigh drug pricesLegislationMedicareU.S. Congress

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

Natasha Yetman  |  January 7, 2020

NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…

Filed under:Drug Updates Tagged with:costsdrug costDrugs

White House Preparing Order that Would Cut Drug Prices for Medicare

Michael Erman and Carl O'Donnell  |  July 30, 2019

(Reuters)—U.S. President Donald Trump is considering a sweeping executive order that would cut prices on virtually all branded prescription drugs sold to Medicare and other government programs, according to two industry sources who had discussions with the White House. The order under discussion would be much broader than the Administration’s previously disclosed proposal to lower…

Filed under:Legislation & Advocacy Tagged with:executive orderMedicare drug price cutMedicare Part BMedicare Part DPrescription drugs

White House Scraps Proposal to Lower U.S. Drug Prices

Caroline Humer  |  July 14, 2019

(Reuters)—The Trump administration on Thursday scrapped one of its most ambitious proposals for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients. The decision represents a new setback to President Donald Trump’s efforts to…

Filed under:Legislation & Advocacy Tagged with:drug pricing blueprintMedicareprescription drug pricesrebate reform initiativerebate ruleTrump administration

Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices

Yasmeen Abutaleb  |  January 11, 2019

WASHINGTON (Reuters)—U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. Democrats have been critical of efforts by the Trump administration to bring down drug prices after President Donald Trump promised to do so during his campaign and since being…

Filed under:Legislation & Advocacy Tagged with:Bernie Sandersdrug costdrug cost legislationElijah Cummings

Pfizer Plans to Increase U.S. Drug Prices in January

Reuters Staff  |  November 19, 2018

NEW YORK (Reuters)—Pfizer Inc. said on Friday that it plans to hike U.S. prices on 41 of its medicines in January, after walking back its previous price increases this summer under pressure from President Donald Trump. The company said in a statement that the increases would be on around 10% of its drugs. Pfizer said…

Filed under:Drug Updates Tagged with:drug costsdrug pricesdrug pricingPfizer Inc.

Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates

Reuters Staff  |  October 25, 2018

WASHINGTON (Reuters)—U.S. President Donald Trump said on Thursday his administration is seeking to lower prescription drug prices by determining the price the government’s Medicare program pays for some medications based on the lower prices paid in other countries. Trump said the move takes aim at what he characterized as “global freeloading” on prescription drugs. “The…

Filed under:Drug Updates Tagged with:lower overseas ratesMedicare drug pricesMedicare's Part B

CVS Rolls Out New Tool to Combat Rising Drug Prices

Reuters Staff  |  April 12, 2018

(Reuters)—Drugstore chain CVS Health Corp on Wednesday launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines. U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising drug prices that has been widely criticized by regulators and has…

Filed under:Technology Tagged with:CVS Health CorpCVS tool

AmerisourceBergen Expects Tumbling Generic Drug Prices to Settle

Anuron Kumar Mitra and Tamara Mathias  |  November 3, 2017

(Reuters)—AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon’s possible entry into the industry. The drug distributor ended its fiscal year with a quarterly loss as it set aside $575 million for legal costs for a…

Filed under:Uncategorized Tagged with:AmerisourceBergen CorpAmerisourceBergen lawsuitlow generic drug prices

  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences